Surface Oncology Valuation
| SURFDelisted Stock | USD 0.96 0.03 3.23% |
Today, the company appears to be overvalued. Surface Oncology has a current Real Value of $0.75 per share. The regular price of the company is $0.96. Our model measures the value of Surface Oncology from inspecting the company fundamentals such as Return On Equity of -1.06, shares outstanding of 60.82 M, and Shares Owned By Institutions of 46.03 % as well as reviewing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Surface Oncology's price fluctuation is very steady at this time. Calculation of the real value of Surface Oncology is based on 3 months time horizon. Increasing Surface Oncology's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Surface stock is determined by what a typical buyer is willing to pay for full or partial control of Surface Oncology. Since Surface Oncology is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Surface Stock. However, Surface Oncology's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.96 | Real 0.75 | Hype 0.96 | Naive 0.87 |
The real value of Surface Stock, also known as its intrinsic value, is the underlying worth of Surface Oncology Company, which is reflected in its stock price. It is based on Surface Oncology's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Surface Oncology's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Surface Oncology helps investors to forecast how Surface stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Surface Oncology more accurately as focusing exclusively on Surface Oncology's fundamentals will not take into account other important factors: Surface Oncology Total Value Analysis
Surface Oncology is at this time projected to have valuation of 18.31 M with market capitalization of 65.69 M, debt of 56.04 M, and cash on hands of 156.65 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Surface Oncology fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
18.31 M | 65.69 M | 56.04 M | 156.65 M |
Surface Oncology Investor Information
About 46.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.47. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Surface Oncology recorded a loss per share of 1.66. The entity had not issued any dividends in recent years. Based on the key measurements obtained from Surface Oncology's financial statements, Surface Oncology is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.Surface Oncology Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Surface Oncology has an asset utilization ratio of 18.76 percent. This implies that the Company is making $0.19 for each dollar of assets. An increasing asset utilization means that Surface Oncology is more efficient with each dollar of assets it utilizes for everyday operations.Surface Oncology Ownership Allocation
Surface Oncology shows a total of 60.82 Million outstanding shares. 30% of Surface Oncology outstanding shares are owned by institutional holders. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Surface Oncology Profitability Analysis
The company reported the previous year's revenue of 30 M. Net Loss for the year was (63.59 M) with loss before overhead, payroll, taxes, and interest of (37 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Surface Oncology's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Surface Oncology and how it compares across the competition.
About Surface Oncology Valuation
The delisted stock valuation mechanism determines Surface Oncology's current worth on a weekly basis. Our valuation model uses a comparative analysis of Surface Oncology. We calculate exposure to Surface Oncology's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Surface Oncology's related companies.Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Surface Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 67 people.
Surface Oncology Growth Indicators
Investing in growth stocks can be very risky. If the company such as Surface Oncology does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 55.8 M |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Other Consideration for investing in Surface Stock
If you are still planning to invest in Surface Oncology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Surface Oncology's history and understand the potential risks before investing.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |